Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression.
Frontiers in Psychiatry 2025 Alexandre Fraichot, Sophie Favre, Hélène Richard-Lepouriel 1 citation
Intranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry. This case report presents the outcome of a 37-year-old patient who received intranasal Esketamine treatment (84 mg) and...